Amazon Escalates GLP-1 War With Ozempic Rollout

Hims & Hers Health, Inc. (HIMS) shares declined by 5% on Thursday after Amazon's move to expand access to Novo Nordisk's oral Ozempic treatment escalated competition in the GLP-1 market.

Amazon Pharmacy now offers real-time medication availability, transparent pricing, and same-day delivery for prescribed oral Ozempic pills, regardless of Prime membership status. The company plans to introduce licensed pharmacist-supported kiosk pickup at select One Medical clinics, allowing patients to receive their medications within minutes of their appointments.

Hims has shifted its focus towards branded GLP-1 therapies after the FDA tightened regulations on compounded Semaglutide and Tirzepatide products. The company already offers branded treatments including Wegovy, Ozempic, Zepbound, and Mounjaro through partnerships with Novo Nordisk and Eli Lilly.

In a bid to stay competitive, Hims has been pushing its AI healthcare strategy ahead of its earnings next week. The company launched Labs AI, an AI-based health assistant embedded into the Hims & Hers platform that helps customers better understand lab tests, biomarker trends, and health risks.